Tricyclic heterocycles as bet protein inhibitors
Abstract:
The present disclosure relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
Public/Granted literature
Information query
Patent Agency Ranking
0/0